共查询到20条相似文献,搜索用时 15 毫秒
1.
P. E. Marchiori M. dos Reis M. E. Quevedo M. Scaff W. Cossermelli J. L. Assis R. M. de Oliveira 《Acta neurologica Scandinavica》1989,80(5):387-389
Radioimmunoassay techniques were used to detect antibodies to the acetylcholine receptor (AAChR) in 164 patients with adult-onset myasthenia gravis. AAChR levels above 0.6 nM/l were considered pathological and were found in 67% of the patients with an average value of 58.99 +/- 125.02 nM/l (0.6-900.0). Correlation, with clinical functional status, the histopathological thymus alterations and the different therapeutics used did not disclose any statistically significant differences. 相似文献
2.
Around 10-20% of myasthenia gravis (MG) patients do not have acetylcholine receptor (AChR) antibodies (seronegative), of whom some have antibodies to a membrane-linked muscle specific kinase (MuSK). To examine MG severity and long-term prognosis in seronegative MG compared with seropositive MG, and to look specifically at anti-AChR antibody negative and anti-MuSK antibody negative patients. Seventeen consecutive seronegative non-thymomatous MG patients and 34 age and sex matched contemporary seropositive non-thymomatous MG controls were included in a retrospective follow-up study for a total period of 40 years. Clinical criteria were assessed each year, and muscle antibodies were assayed. There was no difference in MG severity between seronegative and seropositive MG. However, when thymectomized patients were excluded from the study at the year of thymectomy, seropositive MG patients had more severe course than seronegative (P < 0.001). One seropositive patient died from MG related respiratory insufficiency. The need for thymectomy in seronegative MG was lower than in seropositive MG. None of the seronegative patients had MuSK antibodies. This study shows that the presence of AChR antibodies in MG patients correlates with a more severe MG. With proper treatment, especially early thymectomy for seropositive MG, the outcome and long-term prognosis is good in patients with and without AChR antibodies. 相似文献
3.
Aidong Liu MD Hong Lin MD PhD Yu Liu MD Xinsheng Cao MD Xianni Wang MD Zhuyi Li MD PhD 《Muscle & nerve》2009,40(5):801-808
Acute exacerbation of generalized myasthenia gravis (GMG) can cause swallowing impairment, respiratory failure, or death. It is important to identify immunological factors that might be regarded reliably as an index of the patient's clinical condition, response to treatment, and measure of certain immune aberrations of MG. In this study we investigated correlations between complement component C3, acetylcholine receptor antibody (AChRab) titer, and clinical severity of GMG. AChRab titer and C3 concentration were determined by radioimmunoassay and nephelometry, respectively. The clinical severity of GMG was assessed by the quantitative MG score (QMGS) according to Besinger and colleagues. Our findings indicate that the C3 level correlates with clinical severity of AChRab‐positive GMG. Muscle Nerve, 2009 相似文献
4.
5.
Lifetime course of myasthenia gravis 总被引:1,自引:0,他引:1
Between 1940 and 2000 a total of 1976 patients with myasthenia gravis (MG) were studied. Diagnosis was made by improvement in weakness after anticholinesterase medication. The historical developments in diagnosis and treatment of MG are reviewed. We analyzed the clinical course of MG as influenced by age, gender, thymectomy, thymomectomy, and the presence of antibodies to acetylcholine receptors (AChR). The clinical course of MG was significantly influenced by age and gender, and these need special attention in managing patients. The most severe level of weakness and high mortality occurred during the first 1 to 2 years of the disease, after which many patients experienced improvement. For treating MG patients the usefulness of thymectomy remains to be proven, and novel drugs need to be developed to increase the number as well as normal functioning of the AChRs and other components of the neuromuscular system. 相似文献
6.
Kelvin Y. Teo MBBS Sharon L. Tow FRCSEd Benjamin Haaland PhD Tushar D. Gosavi MRCP LOO Jing‐Liang FRCS LO Yew Long FAMS Dan Milea MD PhD 《Muscle & nerve》2018,57(5):756-760
Introduction: Ocular myasthenia gravis (OMG) is a common condition of the neuromuscular junction that may convert to generalized myasthenia gravis (GMG). Our aim in this study was to determine the conversion rate and predictive factors for generalization in OMG, in an Asian population. Methods: The investigation consisted of a retrospective study of OMG patients with a minimum 2 years of follow‐up. Results: Among 191 patients with OMG, 155 had the minimum 2‐year follow‐up. The conversion rate at median follow‐up (40.8 months) was 10.6% (95% confidence interval 7.9%–13.3%), and at the 2‐year follow‐up it was 7.7% (95% confidence interval 5.6%–9.8%). At baseline, the predictive factors for generalization were positive acetylcholine receptor antibodies (hazard ratio 3.71, P = 0.024), positive repetitive nerve stimulation (RNS) studies (hazard ratio 4.42, P = 0.003), and presence of radiologically presumed or pathologically confirmed thymoma (hazard ratio 3.10, P = 0.013). Discussion: The conversion rate of OMG to GMG in Asian patients is low, as predicted by presence of acetylcholine receptor antibodies, presence of thymoma, and positive RNS studies. Muscle Nerve 57 : 756–760, 2018 相似文献
7.
IgG antibodies to nicotinic acetylcholine receptor (AChR) and to a muscle antigen extracted by citric acid, were quantified in serum and cerebrospinal fluid (CSF) from 28 patients with myasthenia gravis, and the serum:CSF ratios compared with those of total IgG. Agarose-electrophoresis and calculations of the IgG index and Tourtellotte's formula were performed. No evidence of intrathecal antibody synthesis was demonstrated. Compared to the total IgG concentrations in serum and CSF, the CSF concentrations of IgG AChR antibodies were lower than expected. 相似文献
8.
雷诺丁受体(ryanodine receptor, RyR)是存在于内质网/肌质网中的一种重要钙离子通道,在骨骼肌兴奋收缩偶联机制中起重要作用。RyR抗体阳性的重症肌无力(myasthenia gravis, MG)患者常合并胸腺瘤,对常规治疗不敏感,会导致延误临床早期识别及治疗。血清RyR抗体水平与患者临床症状的严重程度显著相关。该文就4例RyR抗体阳性MG患者的临床特点及治疗过程进行讨论并文献复习,旨在提高对RyR抗体阳性MG的认识及诊疗水平。 相似文献
9.
Disease severity and outcome in thymoma myasthenia gravis: a long-term observation study 总被引:4,自引:0,他引:4
F. Romi N. E. Gilhus J. E. Varhaug A. Myking J. A. Aarli 《European journal of neurology》2003,10(6):701-706
Thymomas occurring in myasthenia gravis (MG) are usually of the cortical subtype and are usually treated by thymectomy. However, the factors that influence MG outcome in thymoma MG patients are not known. In a long-term study, MG severity and treatment was observed in 24 thymoma and 24 non-thymoma MG patients for up to 30 years, and the occurrence of muscle autoantibodies was assayed. The rate of complete stable remission was low and did not differ between the two groups. There was no significant difference in MG severity between thymoma and non-thymoma MG patients at any time during the study. Titin and ryanodine receptor (RyR) antibody occurrence was significantly higher in thymoma MG patients. Four thymoma (all titin and RyR antibody positive) and two non-thymoma (both titin and one RyR antibody positive) MG patients died from MG-related respiratory insufficiency. Seventy percent of thymoma and 75% of non-thymoma MG patients were treated with immunosuppressive drugs. The number of patients who received plasmapheresis did not differ in those who were treated because of acute MG deterioration, irrespective of planned surgery.This study shows equal MG severity and outcome in thymoma and non-thymoma MG, but the presence of RyR antibodies in thymoma MG and titin/RyR in non-thymoma MG indicates a less favorable prognosis. 相似文献
10.
Mamatha Pasnoor MD Gil I. Wolfe MD Sharon Nations MD Jaya Trivedi MD Richard J. Barohn MD Laura Herbelin BS April McVey MD Mazen Dimachkie MD John Kissel MD Ronan Walsh MD Anthony Amato MD Tahseen Mozaffar MD Marcel Hungs MD Luis Chui MD Jonathan Goldstein MD Steven Novella MD Ted Burns MD Lawrence Phillips MD Gwendolyn Claussen MD Angela Young MD Tulio Bertorini MD Shin Oh MD 《Muscle & nerve》2010,41(3):370-374
We performed a retrospective chart review on 53 muscle‐specific kinase antibody (MuSK‐Ab)‐positive myasthenia gravis (MG) patients at nine university‐based centers in the U.S. Of these, 66% were Caucasian, 85% were women, and age of onset was 9–79 years. Twenty‐seven patients were nonresponsive to anticholinesterase therapy. Myasthenia Gravis Foundation of America improvement status was achieved in 53% patients on corticosteroids, 51% with plasma exchange, and in 20% on intravenous immunoglobulin (IVIG). Thymectomy was beneficial in 7/18 patients at 3 years. Long‐term (≥3 years) outcome was very favorable in 58% of patients who achieved remission and/or minimal manifestation status. Overall, 73% improved. There was one MG‐related death. This survey reinforces several cardinal features of MuSK‐Ab‐positive MG, including prominent bulbar involvement and anticholinesterase nonresponsiveness. Facial or tongue atrophy was rare. Most patients respond favorably to immunotherapy. The best clinical response was to corticosteroids and plasma exchange, and the poorest response was to IVIG. Long‐term outcome is favorable in about 60% of cases. Muscle Nerve, 2009 相似文献
11.
Judith Burges Angela Vincent Peter C. Molenaar John Newsom-Davis Chris Peers Dennis Wray 《Muscle & nerve》1994,17(12):1393-1400
Muscle weakness in myasthenia gravis is due to autoantibody-induced loss of functional acetylcholine receptors (AChR). About 15% of myasthenia gravis patients, however, do not have detectable anti-AChR antibodies. To investigate the effect of their plasma immunoglobulins on neuromuscular transmission, mice were injected with plasma (and in some cases purified immunoglobulin G (IgG)) from 7 “seronegative” myasthenia gravis (SMG) patients, and neuromuscular transmission parameters were examined. When injected for 15 days, all patients' plasma caused reductions in miniature endplate potential amplitudes, while endplate potential quantal content was significantly reduced by plasma from 4 of the 7 patients. There were no changes in ACh-induced depolarization or single channel properties, and 125l-α-bungarotoxin binding studies showed no effect on AChR number, except in 1 case. Purified IgG injected for 3 days had similar effects to plasma injected for 15 days. Our findings confirm that SMG is autoantibody mediated and that there are pathogenic IgG antibodies. SMG appears to be a heterogeneous disorder and the target(s) for the antibodies may be diverse. © 1994 John Wiley & Sons, Inc. 相似文献
12.
目的探讨重症肌无力(MG)患者血清补体和乙酰胆碱受体抗体(AChRAb)的浓度变化及其相关性。方法对22例MG患者进行糖皮质激素规范化治疗,在治疗前、后检测其血清补体、AChRAb的浓度,并与14例非MG对照组(NC组)作对照,分析两组血清补体和AChRAb变化之间的关系。结果MG组在糖皮质激素治疗前补体C3浓度明显低于NC组(P<0.01),治疗后MG组补体C3明显增高(P<0.05),但仍低于NC组;AChRAb浓度在治疗前MG组明显高于NC组(P<0.01),治疗后MG组AChRAb浓度明显降低(P<0.05),但仍高于NC组。C5浓度MG组和NC组差异无显著性(P>0.05)。但补体(C3、C5)浓度和AChRAb浓度在治疗前(r=0.326、r=0.102,均P>0.05)和治疗后(r=0.114、r=-0.0146,均P>0.05),以及二者治疗前后变化值之间(r=-0.346、r=0.058,均P>0.05)相关性不显著。结论糖皮质激素治疗后MG患者C3浓度增加、AChRAb浓度下降,二者之间无明显相关性,补体和AChRAb在MG发病过程中可能起协同作用。 相似文献
13.
Satoshi Ueno Jin Kang Hiroaki Takeuchi Mitsuo Takahashi Seiichiro Tarui 《Experimental neurology》1980,68(3):512-520
Antibody to acetylcholine receptor from Narke electroplax japonica was isolated from serum of rabbits with experimental autoimmune myasthenia gravis by affinity chromatography on a column of torpedo AChR-agarose conjugates. Sixty-three to eight hundred and ninety-six micrograms of antibody protein were obtained per milliliter myasthenic serum. Serum concentrations of antibody protein correlated with the intensity of the disease and were in exact proportion to the antibody titers of the same samples measured by double immunoprecipitant method. This study showed that anti-AChR antibody played a major role in experimental autoimmune myasthenia gravis and provided the first direct, quantitative evidence that the titers measured by Lindstrom's method could be quite a reliable index of antibody protein concentration in the serum of experimental myasthenia gravis subjects. 相似文献
14.
W.-Z. Wang S. Fredrikson J. Qiao P.-O. Osterman H. Link 《Acta neurologica Scandinavica》1998,98(6):422-426
By enumerating cells secreting IgG antibodies of particular specificities using an enzyme-linked immunospot (ELISPOT) assay, the B-cell responses to Torpedo acetylcholine receptor (AChR) and its α-, β-, γ- and δ-subunits in peripheral blood from patients with myasthenia gravis (MG), and controls with other neurological diseases (OND) as well as healthy subjects were determined. Compared to controls, the patients with MG had elevated numbers of B cells secreting antibodies against AChR and its α-, β-, γ- and δ-subunits in peripheral blood in parallel. The mean numbers of anti-AChR antibody secreting cells were about 17 per 105 blood MNC, and for the subunits 10 to 15 in MG patients, compared to between 0.8 and 1.9 per 105 blood MNC in OND patients, and 0.1 to 0.3 in healthy controls. Such B cells detected in controls probably represent naturally occurring B cells responded to AChR and its subunits. The finding that most (60%) MG patients had B cells predominantly recognizing the α-subunit may be an indirect argument for the existence of a main immunogenic region (MIR). In the remaining 40% of patients with MG the predominant B-cell responses were directed to β-, γ- or δ-subunit. The data suggest that all four AChR subunits may function as strong immunogens in MG, though the α-subunit may be the major immune target in a substantial proportion of MG patients. 相似文献
15.
Neonatal myasthenia gravis : Anti-acetylcholine receptor antibodies in the amniotic fluid 总被引:1,自引:0,他引:1
Evelyne Morel Jean-Franois Bach Marie-Louise Briard Jean-Pierre Aubry 《Journal of neuroimmunology》1984,6(5):313-317
Neonatal myasthenia gravis (NMG) with mild arthrogryposis was observed at birth in the newborn infant of a myasthenic mother. Anti-acetylcholine receptor (anti-AChR) antibodies were present in the serum of both mother and child, in umbilical cord serum and in the amniotic fluid. The presence of anti-AChR antibodies in the amniotic fluid may be one of the causes of the NMG. 相似文献
16.
Qi-Guang Shi Zhi-Hong Wang Xiao-Wei Ma Da-Qi Zhang Chun-Sheng Yang Fu-Dong Shi Li Yang 《神经科学通报》2012,28(5):469-474
Objective To evaluate the frequency, distribution and clinical significance of the antibodies to the fetal and/or adult acetylcholine receptor (AChR) in patients with myasthenia gravis (MG). Methods AChR antibodies were detected by cell-based assay in the serum of ocular MG (OMG) (n = 90) and generalized MG (GMG) patients (n = 110). The fetal-type (2α: β: γ: δ) and adult-type (2α: β: ε: δ) AChR were used as antigens, and their relevance to disease presentation was assessed. Results The overall frequencies of anti-adult and anti-fetal AChR antibodies were similar in all 200 patients examined, with 14 having serum specific to the AChR-γ subunit, and 22 to the AChR-ε subunit. The overall sensitivity when using the fetal and adult AChR antibodies was higher than that when using the fetal AChR antibody only (P = 0.015). Compared with OMG patients, the mean age at disease onset and the positive ratio of antibodies to both isoforms of the AChR were significantly higher in patients who subsequently progressed to GMG. Older patients and patients with both anti-fetal and anti-adult AChR antibodies had a greater risk for developing generalized disease [odds ratio (OR), 1.03; 95% confidence interval (CI), 1.01-1.06 and OR, 5.09; 95% CI, 2.23-11.62]. Conclusion Using both fetal-and adult-type AChRs as the antigens may be more sensitive than using either subtype. Patients with serum specific to both isoforms are at a greater risk of progressing to GMG. Patients with disease onset at an advanced age appear to have a higher frequency of GMG conversion. 相似文献
17.
《Neuromuscular disorders : NMD》2014,24(1):25-30
Most evidence supporting the benefit of thymectomy in juvenile myasthenia gravis (JMG) is extrapolated from adult studies, with only little data concerning paediatric populations. Here we evaluate the outcome of children with generalized JMG who underwent thymectomy between 1996 and 2010 at 2 tertiary paediatric neurology referral centres in the United Kingdom. Twenty patients (15 female, 5 male), aged 13 months to 15.5 years (median 10.4 years) at disease onset, were identified. Prior to thymectomy, disease severity was graded as IIb in 3, III in 11, and IV in 6 patients according to the Osserman classification. All demonstrated positive anti-acetylcholine receptor (AChR) antibody titres. All patients received pyridostigmine and 14 received additional steroid therapy. Transternal thymectomy was performed at the age of 2.7–16.6 years (median 11.1 years). At the last follow-up (10 months to 10.9 years, median 2.7 years, after thymectomy), the majority of children demonstrated substantial improvement, although some had required additional immune-modulatory therapies. About one third achieved complete remission. The postoperative morbidity was low. No benefit was observed in one patient with thymoma. We conclude that thymectomy should be considered as a treatment option early in the course of generalised AChR antibody-positive JMG. 相似文献
18.
19.
F. Romi N. E. Gilhus J. E. Varhaug A. Myking G. O. Skeie & J. A. Aarli 《European journal of neurology》2002,9(1):55-61
Thymectomy is still widely carried out in myasthenia gravis (MG) patients, but its role, especially in late-onset MG patients, is not established. These patients are immunologically heterogeneous, some with thymoma-like and others with early onset-like features. We evaluated whether any therapeutic effects of thymectomy correlate with the presence of non-acetylcholine receptor (AChR) muscle antibodies. The severity of MG, and titin and ryanodine receptor (RyR) antibodies, were assessed yearly starting from MG onset in 21 thymectomized and 22 non-thymectomized AChR antibody positive late-onset MG patients, who were followed for 2, 3 and 5 years. Clinical or pharmacological remission were seen in six of 11 titin antibody negative but none of the 10 titin antibody positive thymectomized patients, however, the non-thymectomized cases showed an opposite trend. The three MG-related deaths were all in patients with titin antibodies. There was no significant difference in MG severity between thymectomized and non-thymectomized patients; 2 years after MG onset, both groups were significantly improved. This study showed no dramatic benefit from thymectomy in late-onset MG in general. Any limited improvement appeared less likely in cases with titin and/or RyR antibodies. 相似文献
20.
Juvenile myasthenia gravis shares a similar pathophysiologic origin with adult myasthenia gravis, but there are important differences, mostly relating to epidemiology, presentation, and therapeutic decision making. Gender ratios and the proportion of seropositive patients differ in the pre‐ and postpubertal age groups. The diagnostic evaluation is similar to that in adults, although special techniques are sometimes necessary to perform single‐fiber electromyography in younger patients. Therapeutic decisions in affected children and adolescents are complicated by the greater long‐term consequences of using steroids, and thus other interventions, such as intravenous immunoglobulin (IVIg) and plasmapheresis, may play a greater therapeutic role in this population than in adults. Steroid‐sparing agents may contribute to the management of refractory cases, but they should be used with caution due to the risk of malignancy. Muscle Nerve, 2008 相似文献